Precision Medicine in Action: Multi-Tracer PET/CT Uncovers Tumor Heterogeneity and a Synchronous Malignancy.

Abstract

Precision oncology leverages molecular profiling to tailor cancer treatment, with nuclear medicine playing an increasingly central role, particularly in elderly patients, where noninvasive approaches are preferable. We present a case of a 76-year-old male with metastatic prostate carcinoma (Gleason score: 5 + 5 = 10) exhibiting neuroendocrine differentiation. Imaging with multiple positron emission tomography (PET) tracers- ⁶⁸ Ga-PSMA, ¹⁸ F-FDG, ⁶⁸ Ga-DOTATATE, and ⁶⁸ Ga-FAPI-revealed significant tumor heterogeneity. Tumor heterogeneity is multifactorial, influenced not only by genetic changes but also by epigenetic, microenvironmental, and therapeutic pressures. While ⁶⁸ Ga-PSMA PET/computed tomography (CT) showed variable expression in osteosclerotic lesions, ¹⁸ F-FDG PET/CT detected metabolic activity, and ⁶⁸ Ga-DOTATATE PET/CT confirmed low somatostatin receptor expression. Despite ¹⁷⁷ Lu-PSMA radioligand therapy, the disease progressed with rising prostate-specific antigen levels. Subsequent gastrointestinal symptoms led to the diagnosis of sigmoid colon adenocarcinoma, confirmed by ⁶⁸ Ga-FAPI PET/CT. This case exemplifies the critical role of nuclear imaging in characterizing tumor biology, guiding therapeutic strategies, and reducing reliance on invasive procedures. The integration of multi-tracer PET imaging enabled a nuanced understanding of tumor evolution, reinforcing nuclear medicine's importance in precision oncology and the management of complex, heterogeneous malignancies.